{"settlement":{"id":"national-opioids-mylan-2026","slug":"national-opioids-mylan-2026","title":"Mylan Settlement","category":"Pharmaceutical and Medical Devices","status":"Claims not yet open","tags":{"industry":["Pharmaceutical and medical devices"],"geographic":["Canada-wide (Except Quebec)"],"recoveryType":["Cash payment"],"documentation":["To be determined"],"eligibilityTrigger":["Was a patient or received treatment"]},"classDefinition":"All persons in Canada (except Quebec) who were prescribed or consumed any opioid Product, together with their heirs, and any member of the Family Law Class. The Family Law Class includes all persons in Canada who, by reason of a relationship to a Class Member, have standing under section 61(1) of Ontario's Family Law Act or equivalent legislation in another province or territory, or the common law.","plainLanguageSummary":"If you were prescribed or consumed prescription opioids in Canada (outside Quebec), or you are a close family member or heir of someone who was, you may be affected by a proposed $200,000 settlement with Mylan Pharmaceuticals that is awaiting court approval.","eligibilityCriteria":[],"recoveryRange":"Share of a $200,000 settlement fund; individual amounts not yet determined","filingInstructions":"","caseBackground":"A national class action claims that several pharmaceutical companies promoted prescription opioids for chronic conditions starting in the 1990s, leading to widespread addiction, and failed to warn about the dangers of taking opioids. The lawsuit was brought on behalf of Canadians who were prescribed or consumed opioids, along with their family members and heirs.\n\nOne of the companies, Mylan Pharmaceuticals ULC, has agreed to a proposed settlement of $200,000 to end the claims against it, while denying the allegations. The lawsuit continues against the other pharmaceutical companies. The Ontario Superior Court of Justice will decide whether to approve the settlement at a hearing on September 16, 2026. A plan for distributing money to class members is expected to be proposed later in 2026, and no claims can be made yet.","administratorName":"","administratorContacts":[],"administratorRole":"claims","agentName":null,"agentContacts":[],"agentClaimFormHelp":false,"classCounselName":"Koskie Minsky LLP","classCounselContacts":[{"type":"phone","label":"","value":"1-833-630-1776"},{"type":"email","label":"","value":"opioidclassaction@kmlaw.ca"},{"type":"mail","label":"","value":"Koskie Minsky LLP, 20 Queen Street West, Suite 900, Toronto, ON, M5H 3R3"},{"type":"online","label":"","value":"https://kmlaw.ca/cases/liability-for-opioid-epidemic/"}],"classCounselFirms":[{"name":"Koskie Minsky LLP","region":"","contacts":[{"type":"phone","label":"","value":"1-833-630-1776"},{"type":"email","label":"","value":"opioidclassaction@kmlaw.ca"},{"type":"mail","label":"","value":"Koskie Minsky LLP, 20 Queen Street West, Suite 900, Toronto, ON, M5H 3R3"},{"type":"online","label":"","value":"https://kmlaw.ca/cases/liability-for-opioid-epidemic/"}]}],"submissionMethods":[],"sourceDocuments":[{"url":"/uploads/5c43796abd8204bf23e856be-Long_Form_Notice_of_Certification_and_Settlement_Approval_Hearing_Mylan.pdf","title":"Notice to Class Members"},{"url":"/uploads/d3230841d7700d2376ae588e-Long_Form_Notice_of_Certification_and_-Settlement_Approval_Hearing_Mylan_FR.pdf","title":"Avis aux membres du groupe"}],"shortFormNoticeUrl":"/uploads/7b16ad036cbf6b7438ccef7c-Short_Form_Notice_of_Certification_and_Settlement_Approval_Hearing_Mylan.pdf","longFormNoticeUrl":"/uploads/5c43796abd8204bf23e856be-Long_Form_Notice_of_Certification_and_Settlement_Approval_Hearing_Mylan.pdf","settlementAgreementUrl":"","claimFormDocumentUrl":"","claimForms":[],"claimFormsButtonLabel":"claim-form","claimFormsUnavailable":false,"claimFormsUnavailableReason":null,"claimFormGuides":[],"additionalDocuments":[],"optOutFormUrl":"","optOutInstructions":"To opt out, you must send a written Opt Out Request to Class Counsel by mail to Koskie Minsky LLP, 20 Queen Street West, Suite 900, Toronto, ON, M5H 3R3, RE: Opioid Class Action. The request must include the case name and court file number (CV-19-00620048-00CP), your full name and address, a declaration that you want to be excluded, whether you consumed a Mylan product, and your signature. The deadline to opt out was May 4, 2026, and it has passed.","objectionFormUrl":null,"objectionInstructions":null,"faqs":[{"answer":"Mylan has agreed to pay $200,000 to settle the claims against it. This amount will be held in an interest-bearing account for the benefit of the class while the lawsuit continues against the other pharmaceutical companies.","question":"How much money is in the settlement?"},{"answer":"Not yet. The settlement must first be approved by the court at a hearing on September 16, 2026. Class Counsel expects to ask the court to approve a plan for distributing the settlement money later in 2026, and will provide notice of how to make a claim at that time.","question":"Can I make a claim for compensation now?"},{"answer":"No. The deadline to object was May 4, 2026, and it has passed. Objections had to be submitted to Class Counsel using an Objection Form.","question":"Can I object to the proposed settlement?"},{"answer":"No. The deadline to opt out was May 4, 2026, and it has passed. Class members who did not opt out remain in the class action and will be bound by the settlement if the court approves it.","question":"Can I opt out of the settlement?"},{"answer":"If you support the proposed settlement, you do not need to do anything. To receive future notices about the settlement, you can register by emailing opioidclassaction@kmlaw.ca. Updates will also be posted at https://kmlaw.ca/cases/liability-for-opioid-epidemic/.","question":"What do I need to do right now?"}],"eligibilityChecker":{"questions":[{"id":"prescribed-or-consumed-opioids","text":"Were you prescribed or did you consume any prescription opioid product?","type":"yes_no","helpText":"If you were not, you may still qualify as a family member or heir of someone who was.","qualifyingAnswer":"yes","criticalForEligibility":true},{"id":"in-canada-outside-quebec","text":"Are you a person in Canada outside of Quebec?","type":"yes_no","qualifyingAnswer":"yes","criticalForEligibility":true},{"id":"family-member-or-heir","text":"If you did not take opioids yourself, are you an heir or a close family member of someone who was prescribed or consumed opioids?","type":"yes_no","helpText":"Family members with standing under family law legislation, such as spouses, children, and parents, may be included.","qualifyingAnswer":"yes","criticalForEligibility":false}],"uncertainMessage":"Some of your answers were Not sure, so we could not confidently determine your eligibility.","qualifyingMessage":"Based on your answers, you appear to fall within the class definition for this settlement.","nonQualifyingMessage":"Based on your answers, you do not appear to fall within the class definition for this settlement."},"claimCategories":[],"proceedings":null,"relatedSlugs":[],"group":{"slug":"opioid-class-action","title":"Opioid Class Action","summary":"Three proposed settlements with Purdue Canada, Valeant and Mylan in the national opioid class action, Gebien v. Apotex, brought on behalf of Canadians who were prescribed or consumed opioid products and allege opioid dependency or addiction. Each settling defendant denies the allegations and the class action continues against the remaining defendants.","membersIntro":null,"structure":"multi_settlement","members":[{"slug":"purdue-canada-opioids-2026","title":"Purdue Canada Settlement","classDefinition":"All persons in Canada, except Excluded Persons, who were prescribed or consumed any opioid Product, together with their heirs, and any member of the Family Law Class (relatives with standing under s. 61(1) of the Family Law Act or equivalent legislation). Excluded Persons include anyone prescribed only OxyContin or OxyNEO between January 1, 1996 and February 28, 2017 and no other Products, officers or directors of the defendants, and members of the class in the Bourassa Class Action.","status":"Claims not yet open","geographic":["Canada-wide"],"deadline":"","lastVerifiedAt":"2026-08-16","isSelf":false},{"slug":"valeant-opioid-settlement-2026","title":"Valeant and Bausch Health Settlement","classDefinition":"All persons in Canada (except Quebec) who were prescribed or consumed any opioid product (as defined in the Settlement Agreement), together with their heirs, and any member of the Family Law Class. The Family Law Class includes persons who, by reason of a relationship to a Class Member, have standing under section 61(1) of the Family Law Act or equivalent legislation.","status":"Claims not yet open","geographic":["Canada-wide (Except Quebec)"],"deadline":"","lastVerifiedAt":"2026-08-16","isSelf":false},{"slug":"national-opioids-mylan-2026","title":"Mylan Settlement","classDefinition":"All persons in Canada (except Quebec) who were prescribed or consumed any opioid Product, together with their heirs, and any member of the Family Law Class. The Family Law Class includes all persons in Canada who, by reason of a relationship to a Class Member, have standing under section 61(1) of Ontario's Family Law Act or equivalent legislation in another province or territory, or the common law.","status":"Claims not yet open","geographic":["Canada-wide (Except Quebec)"],"deadline":"","lastVerifiedAt":"2026-08-16","isSelf":true}]},"cardSummary":"For people in Canada (outside Quebec) who were prescribed or took prescription opioids, and their close family members. A proposed $200,000 settlement with Mylan Pharmaceuticals awaits court approval.","proofRequired":"","claimTime":"","claimAmount":"","coverageStartDate":"","coverageEndDate":"","deadline":"","optOutDeadline":"2026-05-04","objectionDeadline":null,"approvalHearingDate":"2026-09-16","approvalHearingDates":[{"date":"2026-09-16","label":""}],"approvalPending":false,"seriousHarmEnabled":false,"formHelperEnabled":false,"dateAdded":"2026-08-16","lastUpdated":"2026-08-16","firstPublishedAt":"2026-08-16 16:13:38","claimsOpenedAt":null,"lastVerifiedAt":"2026-08-16","languages":["en","fr"]}}